Recombinant factor VIII liposomal - Opperbas/Omri
Alternative Names: F VIII liposomal - Opperbas/Omri; Factor VIII liposomal - Opperbas/Omri; Recombinant F VIII liposomal - Opperbas/OmriLatest Information Update: 19 Nov 2021
Price :
$50 *
At a glance
- Originator Omri Laboratories; Opperbas Holding
- Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
- Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Haemophilia A
Most Recent Events
- 01 Jun 2004 Factor VIII liposomal is available for licensing (http://www.omrilaboratories.com)
- 01 Jun 2004 Phase-II clinical trials in Haemophilia A in Europe (IV)
- 01 Jun 2004 Phase-II clinical trials in Haemophilia A in Israel (IV)